-+ 0.00%
-+ 0.00%
-+ 0.00%

Smith & Nephew (LSE:SN.) Stock May Trade At A Discount On Cash Flow

Simply Wall St·11/20/2026 23:11:58
语音播报

Smith & Nephew has delivered a 20.9% gain over the past three years, which puts fresh attention on whether the current share price lines up with the cash the business can generate. For anyone watching the stock today, the key question is how that recent share price path compares with the company’s underlying cash flow profile.

  • The 20.9% return over three years raises the question of whether Smith & Nephew’s current valuation is adequately supported by its cash generation.
  • The group’s focus on medical devices means long product lifecycles and recurring procedure volumes, which can support relatively steady cash flows when pricing, reimbursement and operating costs are well managed.
  • Prefer to judge Smith & Nephew on earnings? See what Smith & Nephew's 19.8x P/E says about the price.

The issue now is whether the cash flows that Smith & Nephew is expected to produce, as captured by a Discounted Cash Flow (DCF) intrinsic value estimate, are enough to justify where the shares trade today.

If you are weighing whether Smith & Nephew’s current price matches its cash flow profile, it can help to compare that question across 18 high quality undervalued stocks.

Is Smith & Nephew Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model looks at what Smith & Nephew could return to shareholders in cash over time. On the latest numbers, the group generated trailing twelve month free cash flow of about $893.7 million, which gives a solid starting base for the forecast. Analysts and internal estimates feeding into this 2 Stage Free Cash Flow to Equity model point to growing cash flows rather than a shrinking profile over the coming decade.

Those projected cash flows are discounted back and compared with today’s share price of £11.45. The result of that exercise is that the DCF projections put Smith & Nephew's estimated intrinsic value substantially above the current share price. This suggests the market is valuing the stock cautiously relative to what its cash generation assumptions imply. Find out what Smith & Nephew could be worth using our Discounted Cash Flow (DCF) estimate.

The Smith & Nephew Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up from that valuation question for Smith & Nephew by laying out which assumptions on growth, profitability and earnings need to hold for the shares to be worth meaningfully more or less than today’s price, and sit on the platform’s Community page. Rather than providing a single model output, each narrative sets out the moving parts behind its view of fair value, so you can track those assumptions against future results.

One of the top narratives on Smith & Nephew: 7% undervalued

This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.

"The main priority is execution on the orthopaedics reset, where LANDMARK knees, CATALYSTEM hips, ASC focused robotics and biologics need to offset current weakness..."

Discover why this Narrative puts Smith & Nephew at 7% undervalued.

For Smith & Nephew, the share price is only one piece of the investment puzzle

Even if Smith & Nephew’s valuation looks appealing on cash flow, the research checks have also surfaced specific risk flags that deserve your attention before making any decision. Take a closer look at 1 warning sign before settling on a valuation.